企業プロフィール
Amgen Inc. 株価・ニュース・カタリスト
- ティッカー:
- AMGN
- 取引所:
- NASDAQ
- セクター:
- Generics, Biopharma, Oncology, Immunotherapy
- 所在地:
- Thousand Oaks, California
株価パフォーマンス
407.27 USD (-3.38%)
終値
最終更新: 2026年10月1日
177B USD
時価総額
株価変動の要因
2026年10月1日 時点で AMGN は 3.38% 下落し、$407.27 で取引を終えました。現在のニュース監視期間内に同社の新しいニュースは確認されませんでした。
企業概要
Large-Cap Biotechnology Company
Amgen is a global biotechnology company that discovers, develops, manufactures, and commercializes medicines using human biology, advanced genetics, and protein engineering. Its portfolio spans general medicine, cardiovascular disease, rare disease, inflammation, hematology, and oncology, supported by large-scale biologic manufacturing and a growing small-molecule and RNA-based pipeline.
Obesity and General Medicine
The centerpiece of Amgen's metabolic pipeline is MariTide, an antibody-peptide conjugate that activates the GLP-1 receptor and antagonizes the GIP receptor. Its long-acting design supports monthly, every-eight-week, or quarterly dosing, and the broad MARITIME Phase 3 program covers obesity, type 2 diabetes, cardiovascular outcomes, heart failure, obstructive sleep apnea, treatment switching, and long-term weight maintenance.
Cardiovascular Portfolio
Amgen markets Repatha for LDL cholesterol reduction and is developing olpasiran, an siRNA designed to lower lipoprotein(a). The OCEAN(a) Phase 3 program includes secondary-prevention outcomes, primary-prevention outcomes, and coronary-plaque studies, giving the company multiple approaches to reducing atherosclerotic cardiovascular risk.
Rare Disease Franchise
The Horizon acquisition added UPLIZNA, TEPEZZA, KRYSTEXXA, and TAVNEOS, creating a sizable rare-disease business. Amgen is expanding these assets into new populations while developing dazodalibep, daxdilimab, and AMG 732 across Sjogren's disease, autoimmune disorders, and thyroid eye disease.
Inflammation and Autoimmune Disease
Amgen's inflammation portfolio includes TEZSPIRE, Otezla, and established biologics, with development extending into eosinophilic esophagitis, chronic obstructive pulmonary disease, rheumatoid arthritis, systemic lupus erythematosus, and autoimmune kidney disease. Programs such as blinatumomab and inebilizumab also apply B-cell depletion and T-cell engagement technologies outside oncology.
Oncology and BiTE Platform
The oncology business includes BLINCYTO and IMDELLTRA, both built on Amgen's bispecific T-cell engager platform. IMDELLTRA is being studied across extensive-stage and limited-stage small-cell lung cancer in multiple combinations and dosing formats, while BLINCYTO development continues across leukemia settings and selected autoimmune diseases.
今後のカタリスト
- Initiation of three Phase 3 MariTide studies in people with type 2 diabetes during 2026.
- Completion of two Phase 3 dazodalibep studies in Sjogren's disease in the second half of 2026.
- Completion of the Phase 3 TEZSPIRE study in eosinophilic esophagitis in the second half of 2026.
- Initiation of a Phase 3 UPLIZNA study in chronic inflammatory demyelinating polyneuropathy between the second half of 2026 and the first half of 2027.
最近のニュース
ニュースタイトルは機械翻訳です。詳細は英語の原文をご覧ください。
- 01
- 02
Management commentary keeps pipeline priorities in focus
- 03
Investors watch oncology and cardiometabolic launch cadence
- 04
Regulatory calendar keeps Amgen in the spotlight
- 05
Pipeline updates reinforce the commercial-stage narrative
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。